Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis [0.03%]
免疫检查点抑制剂治疗实体瘤术后复发和转移的不良反应及事件的系统评价和网状Meta分析
Ruiyang Xie,Jie Wu,Bingqing Shang et al.
Ruiyang Xie et al.
Background: By prolonging overall survival and reducing disease recurrence rates, immune checkpoint inhibitors (ICIs) are an emerging adjuvant therapy option for patients with resectable malignant tumors. However, the saf...
Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma [0.03%]
KIAA1429在肺腺癌中的预后影响及免疫作用的综合分析
Lei Guo,Qilin Huai,Bolun Zhou et al.
Lei Guo et al.
Background: Lung adenocarcinoma (LUAD) is the most common lung cancer worldwide. N6-methyladenosine (m6A) methylation is a messenger RNA (mRNA) modification that plays a key role in tumor growth, immune microenvironment, ...
Hannah Bloemen,Kristien Kneepkens,Karen Deraedt et al.
Hannah Bloemen et al.
Background: Neuroendocrine tumors (NETs) are a group of biologically and clinically heterogeneous neoplasms predominantly found in the gastrointestinal and bronchopulmonary tractus. Despite a rising incidence, implementat...
Causal relationship between 14 site-specific cancers and venous thromboembolism [0.03%]
特定癌症与静脉血栓栓塞的因果关系
Xiong Chen,Xiaosi Hong,Shulu Luo et al.
Xiong Chen et al.
Background: It has been observed that cancer and venous thromboembolism (VTE) are associated, but anticancer therapy may violate the causality. Therefore, this study aimed to elucidate the causal relationship of various c...
Hewei Ge,Lixi Li,Di Zhang et al.
Hewei Ge et al.
The current state of oncology medical services is not encouraging and is unable to fully meet the needs of patients with cancer. In recent years, rapidly developing artificial intelligence technology and gradual advancements in mobile phone...
PD-L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR-mutant non-small cell lung cancer cells [0.03%]
针对表皮生长因子受体突变的非小细胞肺癌细胞免疫检查点抑制剂PD-L1阻断会降低奥希替尼的敏感性
Dantong Sun,Puyuan Xing,Junling Li
Dantong Sun
In the previous studies, it was shown that osimertinib plus durvalumab did not achieve satisfactory efficacy, even inferior to osimertinib alone. We found that PD-L1 blockade impaired the efficacy of osimertinib in EGFR-mutant NSCLC cells d...